The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-23. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
== Sources == Magurno, B. A.; Pearlstein, S., eds. (1981). Proceedings of the conference on nuclear data evaluation methods and procedures. BNL-NCS 51363 (PDF). Vol. II. Upton: Brookhaven National Laboratory. Archived (PDF) from the original on March 8, 2021. Retrieved August 6, 2014. Miner, William N.; Schonfeld, Fred W. (1968). "Plutonium". In Clifford A. Hampel (ed.). The Encyclopedia of the Chemical Elements. New York (NY): Reinhold Book Corporation. pp. 540–546. LCCN 68029938.
Social behavior is behavior among two or more organisms within the same species, and encompasses any behavior in which one member affects the other. This is due to an interaction among those members. Social behavior can be seen as similar to an exchange of goods, with the expectation that when one gives, one will receive the same. This behavior can be affected by both the qualities of the individual and the environmental (situational) factors. Therefore, social behavior arises as a result of an interaction between the two—the organism and its environment. This means that, in regards to humans, social behavior can be determined by both the individual characteristics of the person, and the situation they are in.
Aniceto Lacson, November 5, 1898 – July 22, 1899 (to November 27, 1898, in Negros Occidental) Demetrio Larena, November 24, 1898 – November 27, 1898 (in Negros Oriental) President of the Constituent Assembly José Luzuriaga, July 22, 1899 – November 6, 1899 Secretary of War Juan Araneta Civil Governor Melecio Severino, November 6, 1899 – April 30, 1901 Secretary of Justice Antonio Ledesma Jayme, November 5, 1898 – July 22, 1899
=== Soil === Isolates from coal power plant soil are being recognized as pseudomonas and show that they are able to “grow on both the aliphatic and aromatic fractions of petroleum". The aliphatic fraction accounts for the most of crude oil and it is easily broken down by species of pseudomonas. Concentration of naphthene and aromatics components of crude oil noticeably decreased, implying the catabolic flexibleness of pseudomonas isolates. Salam, Obayori, Akashoro, and Okogie say that with incubation of pseudomonas isolates at 1g/L concentration for 21days, 90% of BLCO was broken down which means almost all of aliphatic fragments were vanished and aromatic fragments remarkably decreased. Although there are some microorganisms which are able to degrade crude oil, pseudomonas group shows up as it is the most adaptable. There are two main seasons which are dry and rainy in Nigeria. In the dry season, the temperature of soil varies between 30 and 45 °C, while it changes from 20 to 30 °C during the dry season. The ability of bacteria in soil to break down crude oil is remarkably affected by the average temperatures, pH, and nutrients in the soil that are quite different by seasons. For the experiment that is conducted incubation of Pseudomonas sp and Bacillus sp at the different temperature from 20 to 44 °C and for different time from 6 to 24days, both of bacteria showed the highest amount of degradation of bonny light oil at 36 °C. The amount of degradation of crude oil diversified according to the temperature.
Sources: en.wikipedia.org
== External links == FML – Functional Materials Laboratory of the ETH Zürich Properties and use of magnetic nanoparticle clusters (magnetic nanobeads) Magnetic nanoparticles target human cancer cells Magnetic Nanoparticles Remove Ovarian Cancer Cells from the Abdominal Cavity Wiedwald, U. and Ziemann, P. (Ed.): Properties and applications of magnetic nanoparticles, Thematic Series in the Open Access Beilstein Journal of Nanotechnology. Effects of surfactant on the structural and magnetic properties of hydrothermally synthesized NiFe2O4 nanoparticles
== Chemistry == Pure anhydrous caffeine is a bitter-tasting, white, odorless powder with a melting point of 235–238 °C. Caffeine is moderately soluble in water at room temperature (2 g/100 mL), but quickly soluble in boiling water (66 g/100 mL). It is also moderately soluble in ethanol (1.5 g/100 mL). It is weakly basic (pKa of conjugate acid = ~0.6) requiring strong acid to protonate it. Caffeine does not contain any stereogenic centers and hence is classified as an achiral molecule. The xanthine core of caffeine contains two fused rings, a pyrimidinedione and imidazole. The pyrimidinedione in turn contains two amide functional groups that exist predominantly in a zwitterionic resonance the location from which the nitrogen atoms are double bonded to their adjacent amide carbons atoms. Hence all six of the atoms within the pyrimidinedione ring system are sp2 hybridized and planar. The imidazole ring also has a resonance. Therefore, the fused 5,6 ring core of caffeine contains a total of ten pi electrons and hence according to Hückel's rule is aromatic. Caffeine can be easily protonated to form corresponding caffeinium. This cationic form is the main way in which caffeine exists in acidic solutions.
Samoyeds' friendly and affable disposition makes them poor guard dogs; an aggressive Samoyed is rare. The breed is characterized by an alert and happy expression which has earned the nicknames "Sammie smile" and "smiley dog". With their tendency to bark, however, they can be diligent watch dogs, barking whenever something approaches their territory. Samoyeds are excellent companions, especially for small children or even other dogs, and they remain playful into old age. According to the Samoyed Club of America, when Samoyeds become bored, they may become destructive or start to dig.
== Iron-57 == 57Fe is widely used in Mössbauer spectroscopy and the related nuclear resonance vibrational spectroscopy due to the low natural variation in energy of the 14.4 keV nuclear transition. The transition was famously used to make the first definitive measurement of gravitational redshift, in the 1960 Pound–Rebka experiment.
Interferon beta-1a is available only in injectable forms, and can cause skin reactions at the injection site that may include cutaneous necrosis. Skin reactions with interferon beta are more common with subcutaneous administration and vary greatly in their clinical presentation. They usually appear within the first month of treatment albeit their frequence and importance diminish after six months of treatment. Skin reactions are more prevalent in women. Mild skin reactions usually do not impede treatment whereas necroses appear in around 5% of patients and lead to the discontinuation of the therapy. Also over time, a visible dent at the injection site due to the local destruction of fat tissue, known as lipoatrophy, may develop, however, this rarely occurs with interferon treatment. Interferons, a subclass of cytokines, are produced in the body during illnesses such as influenza in order to help fight the infection. They are responsible for many of the symptoms of influenza infections, including fever, muscle aches, fatigue, and headaches. Many patients report influenza-like symptoms hours after taking interferon beta that usually improve within 24 hours, being such symptoms related to the temporary increase of cytokines. This reaction tends to disappear after 3 months of treatment and its symptoms can be treated with over-the-counter nonsteroidal anti-inflammatory drugs, such as ibuprofen, that reduce fever and pain. Another common transient secondary effect with interferon-beta is a functional deterioration of already existing symptoms of the disease.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.